Guardant Health Inc.
Guardant Health Appoints Former HHS Secretary Alex M. Azar II to Board of Directors
Summary
Guardant Health, Inc. announced on September 12, 2025, the appointment of Alex M. Azar II, former United States Secretary of Health and Human Services, to its Board of Directors, effective immediately. Mr. Azar will serve as a Class III director until the 2027 Annual Meeting of Stockholders. His experience in both government and the private sector is expected to provide strategic insight as Guardant Health advances its mission in precision oncology. He will receive standard compensation for non-employee directors, including stock options and restricted stock units, and is subject to the company's indemnification agreement.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement